Strong Cannabis Classification Did Not Establish Equal Sensitivity Across a Four-Drug Panel
The microfluidic study’s cannabis results did not describe the performance of every drug channel. Benzodiazepine sensitivity was substantially lower in the same authentic-specimen evaluation.
Performance belonged to each target
The authors reported complete agreement for the selected THC-COOH comparisons with their laboratory immunoassay comparator. For benzodiazepines, however, only six of thirteen positive-category specimens produced a positive microfluidic result, corresponding to reported sensitivity of about 46%. Specificity in the drug-free comparison remained high.
One panel can contain different limitations
The discussion identifies antibody recognition of different benzodiazepines and metabolic forms as possible contributors. It also discusses storage and potential pretreatment issues. Those possibilities should remain proposed explanations rather than being presented as proven causes of all seven negative results.
Cannabis validation cannot clear another channel
A device’s overall description as a rapid multidrug screen does not establish uniform detection across targets. Conversely, weaker performance for one class does not erase the observed THC-COOH classifications. A forensic interpretation should identify the analyte-specific comparator, threshold and sample count. A cannabis-positive, benzodiazepine-negative panel does not establish that cannabis was the only exposure. Even an accurately identified urinary metabolite does not identify the only pharmacologically relevant substance at a particular time. This analytical study supports separate reporting of each channel’s observed strengths and limitations.
Related analysis: what the urine platform measured.
Research cited
Ko and colleagues. On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine. ACS Omega (2026). DOI: 10.1021/acsomega.5c11027.
